The Evolution of Genomics Dealmaking
Executive Summary
SmithKline's 1993 $125 million alliance with Human Genome Sciences looked enormously overpriced at the time-and then quickly began to look more reasonable as prices for genomics deals skyrocketed. It was only with the addition of Takeda as a partnerthat the true possibilities of the SB/HGS alliance became evident: if both companies were to market the HGS database to partners, both could benefit.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.